Register Login

MacroGenics Inc (MGNX)

  • Event
  • Oct. 17, 2022, 20:22 UTC

(10% Negative) MACROGENICS, INC. (MGNX) Announces Delay in treatment Trials for certain blood cancers Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 3, 2025, 9:19 a.m.

    📋 MACROGENICS, INC. (MGNX) - Clinical Trial Update

    Filing Date: 2022-10-17

    Accepted: 2022-10-17 16:22:57

    Event Type: Clinical Trial Update

    Event Details:

    MacroGenics Inc (MGNX) Announces Clinical Trial Update MacroGenics Inc (MGNX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: treatment, leader
    • Diseases/Conditions: certain blood cancers
    • Clinical Stage: Phase 1
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: MDS

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: MacroGenics Inc
    • CIK: 0001125345
    • Ticker Symbol: MGNX
    • Period End Date: 2022-10-17
    • Document Type: 8-K

Search

News categories